A recent survey has revealed that approximately three million adults across Canada are currently using GLP-1 medications like Ozempic and Mounjaro, with many more expressing interest but deterred by the high costs. Conducted by Leger Healthcare, the poll highlights a significant shift in consumer behaviour regarding food choices and spending habits as a result of these medications, primarily driven by weight loss and diabetes management.
Changing Eating Habits
The survey indicates that more than half of the participants using GLP-1 drugs have experienced a reduction in appetite, with 40 per cent reporting fewer cravings for food. This has led to notable changes in their dining habits—about 30 per cent are opting for restaurant meals or takeout less frequently. Instead, many are investing in healthier food options, with around one-third stating they are purchasing more fresh fruits, vegetables, and protein-dense foods.
Melicent Lavers-Sailly, the vice-president of research at Leger Healthcare, emphasised the broad implications of these findings. “GLP-1s are no longer a niche health topic. They’re a mainstream consumer and healthcare story,” she noted, pointing out that the influence of these medications extends beyond prescriptions to affect shopping patterns and lifestyle choices.
Financial Barriers to Access
Despite the popularity of GLP-1 drugs, financial constraints remain a significant concern. The survey revealed that over half of those interested in the medications cited lack of insurance coverage or the high cost as deterrents. Approximately 36 per cent of respondents indicated they would be more inclined to use GLP-1s if the risk of side effects were lower. Common gastrointestinal issues, such as nausea and constipation, accompany these medications, although most adverse effects are generally mild.
Notably, 58 per cent of current users stated that weight loss was their primary motivation for taking the drugs, while 42 per cent aimed to manage diabetes. Heart health was also a reason for 22 per cent of users, with men more likely to cite this motivation than women. The cost of these medications can be substantial, with many users paying entirely out of pocket—around a quarter of respondents—and only 28 per cent benefiting from full insurance coverage.
Broader Impacts on Lifestyle Choices
The survey findings extend beyond dietary shifts to encompass lifestyle changes, as GLP-1 users reported increased spending on clothing, beauty products, and fitness services. Approximately 35 per cent of participants mentioned that they now order smaller portions or choose lighter meals, while 36 per cent noted a reduction in alcohol consumption as part of their new health-focused mindset.
Interestingly, the data extrapolated indicates that around two million Canadian adults are keen to start GLP-1 therapy but remain unable to do so, primarily due to financial constraints or concerns about side effects. This illustrates not only a rising demand for effective weight management solutions but also highlights potential disparities in access to healthcare.
Why it Matters
The growing acceptance and use of GLP-1 medications signify a crucial turning point in public attitudes towards weight loss and health management. As these drugs become more mainstream, they challenge traditional narratives around body positivity and societal expectations surrounding health and wellness. Importantly, the survey underscores the need for equitable access to these treatments, suggesting that as demand increases, so too must our commitment to ensuring that all individuals can benefit from advancements in medical science. The implications of this shift will resonate through the healthcare system and society at large, making it essential to address barriers to access while fostering informed conversations around health and body image.
